diabetes meds and incident dementia
Another recent article just came out on positive benefits for GLP-1 receptor agonists as well as SGLT-2 inhibitors, finding a decreased risk of Alzheimer’s disease and related dementias (see dm GLP1 SGLT2 less dementia JamaNeuro2025 in dropbox, or doi:10.1001/jamaneurol.2025.0353 ) Details : -- this was a target trial emulation study using electronic health record data from 2014-2023, from the OneFlorida+ Clinical Research Consortium of patients who were at least 50 years old with type II diabetes and no prior diagnosis of Alzheimer’s disease and related dementias (ADRD) -- this database integrates longitudinal electronic health records linked with the National Death Index for multiple healthcare partners in Florida, with more than 21 million persons covering approximately 86% of Florida’s population, also extending into Georgia and Alabama -- 33,858 eligible patients were included in the GLP1 versus the other second-line glucose loweri...